Enzalutamide (enzalutamide) price changes and out-of-pocket expenses reference after medical insurance

Enzalutamide (Enzalutamide), as a new androgen receptor inhibitor, has significant efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic CRPC. It has been officially launched in China and has been included in the National Medical Insurance Drug List. The implementation of this medical insurance policy has significantly lowered the threshold for patients to purchase drugs, making long-term drug use possible, especially for patient groups with heavy financial burdens, and bringing important drug support.

Before it was included in medical insurance, the domestic market price of the original drug of enzalutamide was relatively high, with each box (usually 40mg After being included in medical insurance, the reimbursement ratio generally ranges from 50% to 70% depending on the region. In some cities, it can even reach 80% or more in the case of special disease outpatient or hospitalization reimbursement. The actual out-of-pocket cost of the patient may be reduced to about a thousand yuan, which greatly alleviates the financial pressure required for long-term treatment. However, the specific amount still depends on the local medical insurance policy. It is recommended to consult a designated hospital or medical insurance service window.

Compared with international prices, foreign original drugs are more expensive without medical insurance support. For example, in the Turkish market, the price of original enzalutamide may be as high as 15,000 or more RMB per box. In order to reduce costs, some patients choose to use overseas generic drugs, such as generic versions produced in Laos or India. The prices of such products range from 1,000 to several thousand yuan, and their ingredients and efficacy are basically the same as the original drugs, making them an optional alternative for some patients.

Overall, the inclusion of enzalutamide in medical insurance has brought tangible financial relief to patients and improved drug accessibility. For patients who are not covered by specific medical insurance or are not covered by reimbursement, they can also choose overseas generic versions as a substitute according to doctor's orders. On the premise of ensuring the safety of medication, rationally choosing regular channels to purchase drugs is the key to ensuring treatment effects and reducing risks.

Reference materials:https://www.drugs.com/